Drug intelligence / Profile preview

KR12

Development stage: Unknown
Lead developer: SPH Biotherapeutics
Modality: Vaccines & Immunotherapeutics, Oncolytic Viruses → Oncolytic Therapeutics
Administration: Rectal, Intraperitoneal, Intravenous, Ophthalmic

Overview

KR12 is a control oncolytic virus vaccine, based on the wild-type herpes simplex virus HSV-1 (F strain), with the Flu-MP gene inserted. It was utilized as a control group in a preclinical study investigating KRAS-mutant oncolytic virus vaccines for metastatic colorectal cancer.

Beyond the preview

Go deeper on KR12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KR12.

Explore the full profile